Gilead Seeks To Limit Sovaldi/Harvoni Royalties In Wake Of Merck's Patent Victory
This article was originally published in The Pink Sheet Daily
As jury hears arguments on damages, Gilead asks court to find Merck was dishonest in obtaining its hepatitis C treatment patents and tries to quash a pricing argument; Merck wants 10% of future sales.
You may also be interested in...
Justice Ginsburg wrote two decisions in pharmaceutical related-cases over the past decade, joined the majority in opinions on the scope of patents, and dissented in decisions giving protection to generic manufacturers and speech of pharmaceutical companies. Her death could impact the outcome of cases challenging the Affordable Care Act.
Neither has announced a firm timeline, and the difference between Pfizer's 'October' and Moderna's 'November' could be mere hours or a few weeks, but Pfizer, by dint of luck or experience, is now in a position to offer the more optimistic projection on when it will seek an EUA. Both firms release their Phase III trial protocols, which seem in line with US FDA guidance.
Agency directs Sprout to disseminate corrective messages about the risks associated with the female sexual dysfunction pill. Sprout previously challenged FDA’s alcohol labeling requirements.